Editor's Note The widespread adoption of GLP-1 weight-loss medications like Ozempic and Wegovy could put revenue at risk across multiple service lines, according to a March 11 article in Becker’s Hospital Review. As a result, hospitals and ambulatory surgery centers (ASCs) face critical questions about how to adapt. The article…

Read More

Editor's Note Preoperative use of GLP-1 receptor agonists was not significantly associated with an increased risk of aspiration pneumonia or acute respiratory failure after surgery, according to a March 4 report in MedPage Today. The article focuses on a retrospective cohort study of over 366,000 surgical patients found no meaningful…

Read More

Editor's Note Known for managing Type 2 diabetes and promoting weight loss, GLP-1 drugs like Ozempic and Wegovy may also reduce the risks of numerous other conditions, including Alzheimer’s, substance use disorders, and certain cancers, according to an article published in Fortune January 20. Led by the Veterans Affairs St.…

Read More

Editor's Note Despite a rise in discussions about bariatric surgery, a retrospective study spanning two decades revealed persistent racial and gender disparities in which patients undergo the procedure. MedPage Today reported the news January 16. The analysis, involving 122,487 patients, showed that only 9.1% with class II obesity or higher…

Read More

Editor's Note A recent survey from Orlando Health highlights limited awareness of the link between bariatric surgery and improved fertility, with only half of respondents acknowledging its benefits. According to January 16 coverage in Contemporary OB/GYN, the findings underscore a broader knowledge gap among the US population regarding the role…

Read More

Editor's Note GLP-1 drugs may improve surgical outcomes without increasing risks for diabetic patients, according to a January 7 article in Medical Xpress. The article covers a study published in the Annals of Surgery finding that GLP-1 receptor agonists, such as semaglutide and tirzepatide, significantly reduced certain surgical complications in…

Read More

Editor's Note Bariatric surgery programs nationwide have reported a 20-25% decline in surgical volumes over the past year amid the rising use of glucagon-like peptide-1 (GLP-1) medications for obesity, OR Management News reported Dec 2. Although the connection between the decline and the popularity of the drugs cannot be definitively…

Read More

Editor's Note An analysis of trends in body mass index (BMI) and obesity among US adults from 2013 to 2023 reveals a slight but significant decline in obesity prevalence in 2023, marking the first decrease after years of steady increases. The findings are detailed in a December 13 JAMA Health…

Read More

Editor's Note Access to GLP-1 medications is improving as manufacturers, insurers, and policymakers address high demand, costs, and coverage challenges, Becker’s Hospital Review reported December 13. As detailed in the article, Eli Lilly’s partnership with telehealth company Ro now allows patients to obtain Zepbound prescriptions online and receive shipments directly…

Read More

Editor's Note Demand for skin removal surgeries has risen sharply in the US, fueled by the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, CNN reported December 9. The trend reflects a growing need for procedures that address loose, sagging skin following significant weight loss, particularly as the…

Read More